BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Given Average Rating of “Moderate Buy” by Analysts

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $25.00.

A number of brokerages have recently commented on BBOT. Wall Street Zen lowered shares of BridgeBio Oncology Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. HC Wainwright lifted their price target on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a “buy” rating in a report on Friday, March 6th. Canaccord Genuity Group initiated coverage on shares of BridgeBio Oncology Therapeutics in a report on Monday, May 11th. They issued a “buy” rating and a $23.00 target price on the stock. Finally, Stifel Nicolaus assumed coverage on BridgeBio Oncology Therapeutics in a research report on Tuesday, February 10th. They set a “buy” rating and a $23.00 target price on the stock.

BridgeBio Oncology Therapeutics Trading Up 2.5%

Shares of NASDAQ:BBOT opened at $8.23 on Friday. The firm has a market capitalization of $659.31 million, a price-to-earnings ratio of -4.01 and a beta of 0.29. The business’s fifty day simple moving average is $8.68. BridgeBio Oncology Therapeutics has a 52 week low of $7.60 and a 52 week high of $14.87.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($526.11) EPS for the quarter. Research analysts anticipate that BridgeBio Oncology Therapeutics will post -2.31 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BridgeBio Oncology Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. CIBC Private Wealth Group LLC acquired a new position in shares of BridgeBio Oncology Therapeutics during the fourth quarter valued at about $63,000. Persistent Asset Partners Ltd purchased a new position in BridgeBio Oncology Therapeutics during the fourth quarter worth about $107,000. Squarepoint Ops LLC purchased a new position in BridgeBio Oncology Therapeutics during the fourth quarter worth about $144,000. Quadrature Capital Ltd purchased a new position in BridgeBio Oncology Therapeutics during the fourth quarter worth about $162,000. Finally, BIT Capital GmbH purchased a new position in BridgeBio Oncology Therapeutics in the fourth quarter valued at about $313,000. 54.89% of the stock is owned by institutional investors.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.